Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Stakk Secures T-Mobile Contract to Power Super App Expansion
    Stakk Secures T-Mobile Contract to Power Super App Expansion
    • News

  • Medibank Backs Emyria with Landmark Depression Care Deal
    Medibank Backs Emyria with Landmark Depression Care Deal
    • News

  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    • News

  • BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    • News

  • Harris Technology eyes profitability as refurbished tech sales surge
    Harris Technology eyes profitability as refurbished tech sales surge
    • News

  • QIC Fund Backs Ark Mines with $4.5m to Accelerate Sandy Mitchell Development
    • News

  • Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    • News

  • FBR’s tech could help reduce housing construction-related cost pressures
    FBR’s tech could help reduce housing construction-related cost pressures
    • News

  • Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    • News

  • June 2025 quarter CPI no roadblock to August RBA rate cut
    June 2025 quarter CPI no roadblock to August RBA rate cut
    • News

Imugene Advances Cancer Fight with 57% Complete Response Rate in CAR-T Trial

  • In News
  • February 14, 2025
  • Gracen Moore
Imugene Advances Cancer Fight with 57% Complete Response Rate in CAR-T Trial

Industry Opportunity: Addressing a Critical Unmet Need

The fight against blood cancer is evolving, and Imugene Limited (ASX:IMU) is at the forefront of this battle. With a new wave of promising results from its Phase 1b trial, Imugene’s allogeneic off-the-shelf CD19 CAR-T therapy, azer-cel, is demonstrating significant potential for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

DLBCL is one of the most common and aggressive forms of non-Hodgkin’s lymphoma, with over 30,000 new cases annually in the U.S. Many patients relapse after multiple lines of therapy, including autologous CAR-T treatment, leaving them with limited options. This is where azer-cel steps in.

New Data: More Patients Achieving Complete Responses

Two more patients in the trial have now achieved a Complete Response (CR), bringing the total to four out of seven in Cohort B.

“All four Complete Responses in this cohort were observed in patients who had already failed at least four prior treatments, including autologous CAR-T therapy,” said Dr. Paul Woodard, Chief Medical Officer at Imugene.

This latest data highlights azer-cel’s potential as a game-changing treatment for those who have exhausted traditional options.

Azer-cel Shows Promise in Difficult Cases

The trial’s results are particularly encouraging given the tough-to-treat nature of this patient population.

“The fact that we’re seeing responses in patients who previously had no success with other therapies suggests that azer-cel, when combined with IL-2, could provide a new lifeline,” Dr. Woodard added.

The longest durability of response is currently ongoing at 10 months, with further updates expected as the data matures.

Expanding Trial Sites in the U.S. and Australia

Imugene is actively expanding the trial, with 13 sites in the U.S. and up to five sites in Australia set to enrol patients.

“This is a critical step in ensuring that more patients can access this promising therapy,” Dr. Woodard said.

The company remains focused on continuing enrolment in Cohort B and evaluating the long-term durability of responses.

Industry Recognition and Next Steps

Imugene’s breakthrough with azer-cel is attracting attention from the global medical community. A poster presentation on the trial results was featured at the 2025 American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR) Tandem Meetings event, a key industry event highlighting the latest advancements in transplantation and cellular therapy.

“Sharing our data with the international scientific community allows us to further validate our findings and accelerate progress,” Dr. Woodard said.

Investors and industry observers will be watching closely as Imugene continues to advance its immunotherapy pipeline. With an increasing focus on allogeneic CAR-T therapies as a viable alternative to traditional approaches, the company is positioning itself as a leader in next-generation cancer treatments.

  • About
  • Latest Posts
Gracen Moore
Latest posts by Gracen Moore (see all)
  • Stakk Secures T-Mobile Contract to Power Super App Expansion - September 30, 2025
  • Medibank Backs Emyria with Landmark Depression Care Deal - September 22, 2025
  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI - September 19, 2025
  •  
  •  
  •  
  •  
  • ASX:IMU
  • News

Leave a Comment

You must be logged in to post a comment.

1 Comment

  • Shraddha13
    February 14, 2025, 8:33 pm

    Thank you for sharing! To explore further
    https://www.360iresearch.com/library/intelligence/cd19-targeted-car-t-cell-therapy

    Reply
  • About
  • Latest Posts
Gracen Moore
Latest posts by Gracen Moore (see all)
  • Stakk Secures T-Mobile Contract to Power Super App Expansion - September 30, 2025
  • Medibank Backs Emyria with Landmark Depression Care Deal - September 22, 2025
  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI - September 19, 2025

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Gracen Moore
Latest posts by Gracen Moore (see all)
  • Stakk Secures T-Mobile Contract to Power Super App Expansion - September 30, 2025
  • Medibank Backs Emyria with Landmark Depression Care Deal - September 22, 2025
  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI - September 19, 2025
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.